<DOC>
	<DOCNO>NCT02912026</DOCNO>
	<brief_summary>Open label radiolabelled metabolism study intravenous oral solution form F901318 . Five healthy male subject receive IV five receive oral solution . Blood , urine faeces collect period adequate obtain 90 % recovery parent compound determine metabolic profile IV oral form .</brief_summary>
	<brief_title>Radiolabelled IV Oral Metabolism Study F901318</brief_title>
	<detailed_description>Subjects screen eligibility participate study 28 day dose . Eligible subject admit clinical unit even Day -1 prior investigational medicinal product ( IMP ) administration , dose morning Day 1 . In Cohort 1 ( Regimen A ) , subject dose light breakfast ; ass tolerability IV administration , first subject dose least 30 min prior dose second subject . All subsequent dosing IV formulation stagger least 15 min . In Cohort 2 ( Regimen B ) , subject dose follow overnight fast appropriate interval subject base logistical requirement . Subjects remain resident clinic 336 h post-dose ( Day 15 ) . It plan subject return clinical unit 2 24 h residency period Day 21 Day 28 discharge criterion outline protocol met . It plan subject release study group subject achieve mass balance cumulative recovery &gt; 90 % &lt; 1 % dose administer collected urine faeces within 2 separate , consecutive 24 h period . If occurs earlier Day 28 , collection sample ( blood , urine faeces ) stop subject undergo discharge assessment . If criterion meet subject follow Day 28 return visit , home collection urine faeces may request discretion investigator individual subject .</detailed_description>
	<mesh_term>Aspergillosis</mesh_term>
	<criteria>1 . Healthy male wish father child within 6 month follow IMP administration . 2 . Age 40 65 year age time sign ICF . 3 . Body mass index 18.0 35.0 kg/m2 , weight 50 100 kg . 4 . Must willing able communicate participate whole study . 5 . Subjects must good health determine medical history , physical examination , 12lead ECG clinical laboratory evaluation . 6 . Must regular bowel movement ( ie , average stool production ≥1 ≤3 stool per day ) . 7 . Must provide write informed consent agree abide study restriction 8 . Must agree use adequate method contraception study 6 month study discharge 1 . Subjects receive IMP clinical research study within previous 3 month prior dose . 2 . Subjects study site employee , immediate family member study site sponsor employee . 3 . Subjects previously enrol study previously expose F901318 . 4 . History drug alcohol abuse past 2 year . 5 . Regular alcohol consumption male &gt; 21 unit per week ( 1 unit = ½ pint beer , 25 mL 40 % spirit 125 mL glass wine ) . 6 . Current smoker smoke used nicotine containing product ( eg electronic cigarette ) within last 6 month . A confirm positive urine cotinine test screen admission . 7 . Radiation exposure , include present study , exclude background radiation include diagnostic xrays medical exposure , exceed 5 mSv last 12 month 10 mSv last 5 year . No occupationally expose worker , define Ionising Radiation Regulations 1999 , shall participate study . 8 . Subjects suitable vein multiple venepunctures/cannulation assess investigator screening .</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>